Hint mode is switched on Switch off

Moderna, Brazilian depositary receipt (GDR)
BRM1RNBDR006, M1RN34

Add a stock to WL
Choose all Reset all
Moderna, сountry — USA
No trading data
Data display in a chart | table
Source of information - PJSC "MOEX". Further disctribution of MOEX information is prohibited without prior consent with PJSC "MOEX".
Source of information - PJSC "MOEX". Further disctribution of MOEX information is prohibited without prior consent with PJSC "MOEX".
from
to
ADD-IN
Cbonds add-in API
bond data api
Authorization required
You need to request access
More than 2,500 records have been found, please specify your request
No data for the selected period

explore the most comprehensive database

900 000

bonds globally

Over 400

pricing sources

80 000

stocks

116 000

ETF & Funds

track your portfolio in the most efficient way

  • Bond Search
  • Watchlist
  • Excel ADD-IN
Get access
×

— Are you looking for the complete & verified bond data?

— We have everything you need:

full data on over 900 000 bonds, 80 000 stocks, 116 000 ETF & Funds; powerful bond screener; over 350 pricing sources among stock exchanges & OTC market; ratings & financial reports; user-friendly interface; available anywhere via Website, Excel Add-in and Mobile app.

Register
×

Why

You will have detailed descriptive & pricing data for 650K bonds, 76K stocks, 8K ETFs
Get full access to the platform from any device & via Cbonds app
Enhance your portfolio management with Cbonds Excel Add-in
Build yield maps, make chart comparison within a click
Don't wait any longer — start using Cbonds today! Register

Latest quotes

Issuer

Profile
Moderna, Inc. develops medicines based on messenger RNA (mRNA). Its pipeline includes development candidates for mRNA-based vaccines and therapies for use in various therapeutic areas comprising prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic ...
Moderna, Inc. develops medicines based on messenger RNA (mRNA). Its pipeline includes development candidates for mRNA-based vaccines and therapies for use in various therapeutic areas comprising prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics.
Show more Hide
  • Issuer
  • Full borrower / issuer name
    Moderna, Inc.
  • Industry
    Pharmaceutical Preparation and Biotechnology

IFRS/US GAAP reports

2024
I q eng
2023
I q eng
II q eng
III q eng
IV q eng
2022
I q eng
II q eng
III q eng
IV q eng
2021
I q eng
II q eng
III q eng
IV q eng
2020
I q eng
II q eng
III q eng
IV q eng
2019
I q eng
II q eng
III q eng
IV q eng
2018
IV q eng
Show all Hide

Indicators

News

10/06/2025 Vaccine Panel Overhaul Weighs on Moderna, Pfizer, BioNTech Shares
01/05/2025 Moderna Inc. (NASDAQ: MRNA) Quarterly Earnings Preview
30/04/2025 Moderna: Submission Of Matters To A Vote Of Security Holders
14/02/2025 Moderna, Inc. (NASDAQ:MRNA) Faces Challenges and Opportunities in Biotech Sector
13/02/2025 Moderna Inc. (NASDAQ:MRNA) Quarterly Earnings Preview
All organization news

Other stocks and deposit receipts

Holders

Industry Leaders

Registration is required to get access.